在患有阿尔茨海默氏病频谱障碍的患者中,功能连接的频率依赖性改变
Hanjun Hu1,2, Luoyu Wang2,3, Sammad Abdul4
1The Fourth Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.
Frontiers in aging neuroscience
|April 12, 2024
概括
这项研究揭示了阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 中的大脑连接模式在各种频段,特别是慢-5频段中存在显著差异. 这些发现强调了在AD神经成像研究中考虑频率特异分析的重要性.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 认知科学 认知科学
背景情况:
- 阿尔茨海默氏症 (AD) 和相关疾病可能会在脑皮层的静止状态功能磁共振成像 (rs-fMRI) 信号特征中显示出不同的频率范围.
- 在全脑功能连接的背景下,这个假设仍然未被充分研究.
- 在频段中调查度中心性 (DC) 和声镜镜同型连接 (VMHC) 的变化对于理解AD和轻度认知障碍 (MCI) 至关重要.
研究的目的:
- 探索在患有amnestic轻度认知障碍 (aMCI) 和AD的个体中DC和VMHC的潜在修改.
- 评估这些变化是否在不同的rs-fMRI频段中存在差异.
- 增强对AD连续体中的病理和生理机制的理解.
主要方法:
- 该研究包括53名AD患者,40名aMCI患者和40名健康对照 (HC).
- DC和VMHC在经典 (0.01-0.08 Hz),慢-4 (0.027-0.073 Hz) 和慢-5 (0.01-0.027 Hz) 频段内进行计算.
- 使用ANOVA,后期t测试和皮尔森相关性分析来评估群体差异和认知关联.
主要成果:
- 在频段之间观察到DC的显著群体差异,特别是在双边尾状核,中间上额头,小脑叶片和左前.
- VMHC差异主要局限于后带带状回形和小脑Crus II.
- 慢-5频段表现出最多的大脑区域具有显著差异.
结论:
- 该研究揭示了AD和aMCI患者在不同频段的大脑连接 (DC和VMHC) 的显著变化.
- 研究结果表明,慢-5频段对AD连续性内的大脑功能变化特别敏感.
- 研究人员应该考虑在rs-fMRI脑功能研究中分析各种频段,以更好地了解神经退行性疾病.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.缓慢的认知障碍 缓慢的认知障碍中心性的程度.静止状态的功能磁共振成像技术慢-5频段的频率带是一个缓慢的频段.沃克塞尔镜像同位体连接 voxel-mirrored 同位体连接更多相关视频
09:01A Method for Investigating Age-related Differences in the Functional Connectivity of Cognitive Control Networks Associated with Dimensional Change Card Sort Performance
Published on: May 7, 2014
10.2K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
